Sanofi: Settlement with Lilly about SoloStar litigation

BUY, Fair Value EUR103 vs. EUR102 (+22%)
News published on September Tuesday 29, 2015
Share on

Sanofi and Lilly have settled their patent dispute in the US. As a consequence, biosimilar Lantus SoloStar will not hit the US market before mid December next year. 2016 is therefore likely to be clean of major headwinds and Sanofi is given 6 extra months to transform its Diabetes franchise.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities